Loading company…
ViraTherapeutics GmbH develops immunotherapy drugs based on oncolytic viruses to target cancer cells.
ViraTherapeutics GmbH develops immunotherapy drugs that use a patented modified Vesicular Stomatitis Virus (VSV-GP) to target and destroy cancer cells. Founded in 2013 and headquartered in Innsbruck, Austria, the company is at the Series A stage. Boehringer Ingelheim International GmbH acquired it in September 2018 for EUR 210 million in a Trade Sale, and Knut Elbers is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in